Featured Publications

A Stanford team used MIBI-based spatial proteomics to understand the inflammatory state of immunotherapy-driven gastritis  


Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis

Ferrian, et al., Cell Reports Medicine  19 Oct 2021, 2(10), 100419.

Key Insights
  • Scientists from Stanford University and the University of California, Los Angeles, performed an investigation of gastrointestinal side effects from immune checkpoint PD-1 cancer therapy based on a patient with Lynch syndrome and eight healthy controls.
  • They used MIBI™ technology to image gastric tissue samples and analyze 28 markers, revealing key molecular drivers of the inflammatory state.
  • These discoveries will fuel future studies of immunotherapy-induced inflammation in the GI tract to inform better treatment strategies for patients with cancer and related conditions.

Immune checkpoint blockade using PD-1 inhibition is an effective approach for treating a wide variety of cancer subtypes. While lower gastrointestinal (GI) side effects are more common, upper gastrointestinal adverse events are rarely reported. Here, we present a case of nivolumab-associated autoimmune gastritis. To elucidate the immunology underlying this condition, we leverage multiplexed ion beam imaging by time-of-flight (MIBI-TOF) to identify the presence and proportion of infiltrating immune cells from a single section of biopsy specimen. Using MIBI-TOF, we analyze formalin-fixed, paraffin-embedded human gastric tissue with 28 labels simultaneously. Our analyses reveal a gastritis characterized by severe mucosal injury, interferon gamma (IFN-γ)-producing gastric epithelial cells, and mixed inflammation that includes CD8 and CD4 T cell infiltrates with reduced expression of granzyme B and FOXP3, respectively. Here, we provide a comprehensive multiplexed histopathological mapping of gastric tissue, which identifies IFN-γ-producing epithelial cells as possible contributors to the nivolumab-associated gastritis.

Contact Us

<p style="text-align: center; margin-top: 2em;">Let us know how we can help you.</p>

    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther


    Please contact me. I understand that I can choose to unsubscribe at any time by e-mailing marketing@ionpath.com.

    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.